BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND PTPRC, LCA, 5788, ENSG00000081237, T200, GP180, B220, LY5, CD45 AND Prognosis
10 results:

  • 1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer.
    Bartl T; Alberts A; Papadopoulos SC; Wolf A; Muellauer L; Hofstetter G; Grimm C; Cacsire Castillo-Tong D
    Int J Gynecol Cancer; 2023 Sep; 33(9):1419-1426. PubMed ID: 37094966
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
    Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
    BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade ovarian Serous Carcinoma.
    Ruano APC; Gadelha Guimarães AP; Braun AC; Flores BCTCP; Tariki MS; Abdallah EA; Torres JA; Nunes DN; Tirapelli B; de Lima VCC; Fanelli MF; Colombo PE; da Costa AABA; Alix-Panabières C; Chinen LTD
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499015
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic and Clinical Value of Interleukin 6 and cd45
    Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
    J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
    Chebouti I; Blassl C; Wimberger P; Neubauer H; Fehm T; Kimmig R; Kasimir-Bauer S
    Oncotarget; 2016 May; 7(18):26454-64. PubMed ID: 27049920
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
    Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
    Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours.
    Rainczuk A; Rao JR; Gathercole JL; Fairweather NJ; Chu S; Masadah R; Jobling TW; Deb-Choudhury S; Dyer J; Stephens AN
    Int J Cancer; 2014 Feb; 134(3):530-41. PubMed ID: 23873303
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. ovarian lymphoma.
    Bambury I; Wharfe G; Fletcher H; Williams E; Jaggon J
    J Obstet Gynaecol; 2011 Oct; 31(7):653-5. PubMed ID: 21973136
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
    Poveda A; Kaye SB; McCormack R; Wang S; Parekh T; Ricci D; Lebedinsky CA; Tercero JC; Zintl P; Monk BJ
    Gynecol Oncol; 2011 Sep; 122(3):567-72. PubMed ID: 21664658
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.